Pyxis Oncology to Participate in the BTIG Virtual Biotechnology Conference
2024年7月29日 - 9:00PM
Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company
focused on developing next generation therapeutics to target
difficult-to-treat cancers, announced today that Lara S. Sullivan,
M.D., President and Chief Executive Officer, and members of
management will participate in one-on-one meetings at the BTIG
Virtual Biotechnology Conference being held August 5-6, 2024.
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc. is a clinical stage company focused on
defeating difficult-to-treat cancers. The company is efficiently
building next generation therapeutics that hold the potential for
mono and combination therapies. PYX-201, an antibody-drug conjugate
(ADC) that uniquely targets EDB+FN within the tumor stroma, and
PYX-106, a fully human Siglec-15-targeting antibody designed to
block suppression of T-cell proliferation and function, are being
evaluated in ongoing Phase 1 clinical studies in multiple types of
solid tumors. Pyxis Oncology’s therapeutic candidates are designed
to directly kill tumor cells and to address the underlying
pathologies created by cancer that enable its uncontrollable
proliferation and immune evasion. Pyxis Oncology’s ADC and
immuno-oncology (IO) programs employ novel and emerging strategies
to target a broad range of solid tumors resistant to current
standards of care. To learn more,
visit www.pyxisoncology.com or follow us
on Twitter and LinkedIn.
Forward Looking Statements This press release
contains forward-looking statements for the purposes of the safe
harbor provisions under The Private Securities Litigation Reform
Act of 1995 and other federal securities laws. These statements are
often identified by the use of words such as “anticipate,”
“believe,” “can,” “continue,” “could,” “estimate,” “expect,”
“intend,” “likely,” “may,” “might,” “objective,” “ongoing,” “plan,”
“potential,” “predict,” “project,” “should,” “to be,” “will,”
“would,” or the negative or plural of these words, or similar
expressions or variations, although not all forward-looking
statements contain these words. We cannot assure you that the
events and circumstances reflected in the forward-looking
statements will be achieved or occur and actual results could
differ materially from those expressed or implied by these
forward-looking statements. Factors that could cause or contribute
to such differences include, but are not limited to, those
identified herein, and those discussed in the section titled “Risk
Factors” set forth in Part II, Item 1A. of the Company’s Annual
Report on Form 10-K filed with SEC on March 21, 2024, and our other
filings, each of which is on file with the Securities and Exchange
Commission. These risks are not exhaustive. New risk factors emerge
from time to time, and it is not possible for our management to
predict all risk factors, nor can we assess the impact of all
factors on our business or the extent to which any factor, or
combination of factors, may cause actual results to differ
materially from those contained in any forward-looking statements.
In addition, statements that “we believe” and similar statements
reflect our beliefs and opinions on the relevant subject. These
statements are based upon information available to us as of the
date hereof and while we believe such information forms a
reasonable basis for such statements, such information may be
limited or incomplete, and our statements should not be read to
indicate that we have conducted an exhaustive inquiry into, or
review of, all potentially available relevant information. These
statements are inherently uncertain, and investors are cautioned
not to unduly rely upon these statements. Except as required by
law, we undertake no obligation to update any forward-looking
statements to reflect events or circumstances after the date of
such statements.
Pyxis Oncology Contact Pamela
Connealy CFO and COO ir@pyxisoncology.com
Pyxis Oncology (NASDAQ:PYXS)
過去 株価チャート
から 7 2024 まで 8 2024
Pyxis Oncology (NASDAQ:PYXS)
過去 株価チャート
から 8 2023 まで 8 2024